Previous Close | 21.88 |
Open | 21.78 |
Bid | 21.24 x 200 |
Ask | 21.32 x 200 |
Day's Range | 21.25 - 22.06 |
52 Week Range | 15.99 - 26.42 |
Volume | |
Avg. Volume | 183,890 |
Market Cap | 763.913M |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
DALLAS, May 15, 2024--Thryv's AI and Small Business survey reveals the advantages AI is bringing to SMBs and the money and time savings they expect to see from using it.
Thryv Therapeutics Inc., a biotechnology company pioneering precision treatment to treat indications including Congenital Long QT Syndrome, atrial fibrillation, and heart failure, today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA. This presentation will take place on Friday, May 17th, from 10:30 a.m. to 12:30 p.m. ET. The meeting will commence with a presentation by Thryv co-founder and Princi
DALLAS, May 06, 2024--Thryv Holdings, Inc. (NASDAQ:THRY) ("Thryv" or the "Company"), the provider of Thryv®, the leading small business software platform, announced today members of its management team will host 1:1 meetings at the following upcoming investor conferences: